NCT07506109 2026-04-07A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal CancerTianjin Medical University Cancer Institute and HospitalPhase 2 Recruiting49 enrolled